Compare WTFC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTFC | GKOS |
|---|---|---|
| Founded | 1991 | 1998 |
| Country | United States | United States |
| Employees | 5902 | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.7B |
| IPO Year | N/A | 2015 |
| Metric | WTFC | GKOS |
|---|---|---|
| Price | $161.60 | $150.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $168.07 | $126.92 |
| AVG Volume (30 Days) | 495.3K | ★ 859.5K |
| Earning Date | 04-20-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $13.96 | $23.32 |
| Revenue Next Year | $6.54 | $27.43 |
| P/E Ratio | $13.60 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $119.67 | $73.16 |
| 52 Week High | $164.00 | $150.26 |
| Indicator | WTFC | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 68.14 |
| Support Level | $142.00 | $96.44 |
| Resistance Level | $162.01 | N/A |
| Average True Range (ATR) | 3.31 | 5.59 |
| MACD | 0.20 | 1.67 |
| Stochastic Oscillator | 77.68 | 97.19 |
Wintrust Financial Corp is a financial holding company that provides community-oriented, personal, and commercial banking services to customers generally located in the Chicago metropolitan area, southern Wisconsin, northwest Indiana, and western Michigan. The company provides specialty finance services, including financing for the payment of property and casualty insurance premiums and life insurance premiums, and wealth management services to customers in its market area. Its operations consist of three primary segments: community banking, specialty finance, and wealth management. The company generates the majority of its revenue from the community banking segment.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.